APPENDIX 4

Appendix 4: All-cause Health Care Utilization and Costs during the Entire Follow-up Period - Overall by Treatment

			۸۵	lditionall	v Troot	e alla		Suppo	rtivo	Cara Onl	v[a]			
, , , , , , , , , , , , , , , , , , , ,									,					
				I-Cause I	Utilizat	ion and Co	osts As							
			first-lir		first-line Chemothera py First-line Chemothe py		thera	Second-line Chemotherapy		first-line Chemothera		First-l Chemo py	thera	
(N = 25	583)	(N = 1	(N = 1415)				(N = 1415)		68)	(N = 1 ⁻	168)			
n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)			
	•		•		` '				(72		` '			
2410	(93)	1163	(82)	924	(65)	733	(52)	846)	883	(76)			
3		2		1		1		1		2				
2		2		1		2		2		2				
3		2		1		1		1		1				
23		15		9		7		10		12				
23		19		13		14		16		15				
16		9		5		1		5		8				
		\$29,27		\$23,22						\$30,15				
_		1		3		\$14,320		•		2				
						COE 740								
				_		φ 2 5,719		•		_				
		1				\$4850								
_						Ψ 1000								
2160	(84)	1079	(76)	677	(48)	694	(49)	760	(65	656	(56)			
	Over Follow (N = 29 n 2410 3 2 3 23 23	Follow-up (N = 2583) n (%) 2410 (93) 3 2 3 23 16 \$51,67 2 \$50,66 2 \$38,79 2	Cohort Periods All Pofirst-I Chemo py (N = 2583) n (%) n (%) 2410 (93) 1163 3 2 2 2 3 2 3 2 23 15 23 19 16 9 \$51,67 \$29,27 2 1 \$50,66 \$35,90 2 7 \$38,79 2 1	Cohort Acceptable Periods Of All Post—first-line All Post—first-line Chemothera py (N = 1415) n (%) n (%) 2410 (93) 1163 (82) 3 2 2 2 2 3 2 2 23 15 23 19 16 9 19 \$51,67 2 \$29,27 1 \$50,66 \$35,90 7 \$35,90 7 2 \$38,79 \$18,70 2 1	Cohort Additionallian Periods Of All-Cause of All Post—first-line Chemothera py (N = 2583) First-Chemo py (N = 1415) n (%) n (%) n 2410 (93) 1163 (82) 924 3 2 1 2 2 1 3 2 1 2 1 2 3 2 1 2 1 3 2 1 3 23 19 13 16 9 5 \$51,67 \$29,27 \$23,22 2 1 3 \$50,66 \$35,90 \$30,58 7 6 \$12,52 \$38,79 \$18,70 \$12,52 1 3 3 3	Cohort Additionally Treat Periods Of All-Cause Utilizat All Post–first-line Chemothera py (N = 2583) First-line Chemothera py (N = 1415) First-line Chemothera py (N = 1415) a (%) a (%) a (%) a (%) 2410 (93) 1163 (82) 924 (65) 3 (2) 1 2 2 (3) 2 (65) 1 23 (1) 2 (1) 3 23 (1) 3 (1) 9 23 (1) 3 (1) 9 23 (1) 3 (1) 9 23 (1) 3 (1) 9 551,67 (2) \$29,27 (2) \$23,22 (2) 3 (50) \$35,90 (2) \$30,58 (2) 2 (50) \$18,70 (2) \$12,52 (2) 3 (1) 3 (1) 3 (1)	Cohort Additionally Treated[a] Periods Of All-Cause Utilization and Contact	Cohort	Cohort	Cohort	Cohort			

	Overall										
	Cohort	Ac	Supportive Care Only[a]								
	Periods Of All-Cause Utilization and Costs Assessment [b]										
	Overall Follow-up	Follow-up py		Second-line Chemotherapy	All Post– first-line Chemothera py	First-line Chemothera py					
	(N = 2583)	(N = 1415)	(N = 1415)	(N = 1415)	(N = 1168)	(N = 1168)					
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)					
Number of ED visits)						
Mean	3	3	2	2	2	2					
SD	3	3	1	2	2	2					
Median	3	2	1	2	1	1					
Total ED costs (2012 US \$)		_		_							
Mean	\$416	\$320	\$128	\$159	\$205	\$171					
SD	\$468	\$392	\$214	\$279	\$336	\$263					
Median	\$303	\$207	\$0	\$0	\$146	\$98					
All-cause Office or Specialist											
Visits											
Had ≥1 office or specialist visit,	(10	(10	(10	4.400 (4.00)	(93	(10					
n (%)	2581 0)	1411 0)	1415 0)	1408 (100)	1087)	1166 0)					
Number of office visits	00	40	00		0.0	00					
Mean	66	49	30	29	20	30					
SD	58	47	25	33	43	30					
Median	48	34	23	18	7	21					
Total office or specialist visit costs (2012 US\$)											
+/	\$27,84	\$21,34	\$15,43			\$13,20					
Mean	3	6	1	\$11,727	\$3813	7					

CONDITION LINE OF THE APP	Overa Coho			Ad	lditionally	y Treat	ed[a]		Suppo	rtive	Care Only	y[a]
		Periods Of All-Cause Utilization and Costs Assessment [b]										
	Overall Follow-up		All Post– first-line Overall Chemothera Follow-up py		First-line Chemothera py		Second-line Chemotherapy				First-I Chemot	thera
	(N = 25	•	(N = 14	•	(N = 14	,	(N = 14	•	(N = 11	•	(N = 11	•
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
SD	\$32,41 3 \$17,10		\$30,37 0 \$10,96		\$15,47 4 \$10,40		\$14,405		\$8,209		\$16,12 1	
Median	4		9		3		\$6,416		\$1,304		\$8,088	
All-cause Hospital Outpatient Visits Had ≥1 hospital outpatient visit, n (%) Number of hospital outpatient	2545	(99)	1334	(94)	1367	(97)	1231	(87)	765	(65)	1115	(95)
visits												
Mean	20		15		10		9		5		9	
SD	23		21		10		16		12		10	
Median Total hospital outpatient costs (2012 US \$)	13 \$11,82		9		7		5		1		6	
Mean	5 \$20,48		\$8868 \$19,85		\$6797		\$5657		\$1762 \$10,79		\$5411	
SD	5		5		\$9223		\$16,748		7		\$8347	
Median	\$6182		\$3459		\$4070		\$1800		\$280		\$2755	
All-cause Hospice Visits										(50		
Had ≥1 hospice service, n (%)	1399	(54)	790	(56)	4	(0)	215	(15)	608	(52)	7	(1)

Cohort and Line of Therapy					1	
	Overall		Iditionally Treat	15-7	0	0
	Cohort	•	Supportive Care Only[a]			
			I-Cause Utilizat	ion and Costs As		
	Overall Follow-up	All Post- first-line Chemothera py	First-line Chemothera py	Second-line Chemotherapy	All Post- first-line Chemothera py	First-line Chemothera py
	(N = 2583)	(N = 1415)	(N = 1415)	(N = 1415)	(N = 1168)	(N = 1168)
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Number of hospice visits						
Mean	1	1	0	0	1	0
SD	2	2	0	1	2	0
Median	1	1	0	0	1	0
Total hospice costs (2012 US \$)						
Mean	\$3578	\$3668	\$32	\$1311	\$3380	\$50
SD	\$7901	\$8082	\$766	\$5551	\$7355	\$918
Median	\$547	\$677	\$0	\$0	\$381	\$0
All-cause SNF Care						
Had ≥1 SNF admission, n (%) Number of SNF admissions	598 (23)	252 (18)	101 (7)	131 (9)	(16 182)	133 (11)
Mean	0	0	0	0	0	0
SD	1	1	0	1	1	0
Median Total SNF care costs (2012 US \$)	0	0	0	0	0	0
Mean	\$2989	\$2282	\$712	\$1183	\$1742	\$1240
SD	\$7836	\$6763	\$3542	\$4919	\$6400	\$4633
Median	\$0	\$0	\$0	\$0	\$0	\$0
All-cause Outpatient				·		-

Appendix 4: All-cause Health Care Utilization and Costs during the Entire Follow-up Period - Overall by Treatment

Cohort and Line of Therapy

	Overa Coho			Ac	lditionall	y Treat	ted[a]		Suppo	rtive	Care Onl	y[a]
		Periods Of All-Cause Utilization and Costs Assessment [b]										
	Overall Follow-up (N = 2583)		All Post– first-line Chemothera py (N = 1415)		First-line Chemothera py (N = 1415)		Second-line Chemotherapy (N = 1415)		All Post- first-line Chemothera py (N = 1168)		First-I Chemo py (N = 1	thera
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Pharmacy												
Had ≥1 outpatient pharmacy encounter, n (%) Number of outpatient pharmacy encounters	472	(18)	271	(19)	152	(11)	218	(15)	178	(15)	139	(12)
Mean	10		10		2		5		5		3	
SD	35		33		10		24		24		16	
Median Total outpatient pharmacy encounter costs (2012 US \$)	0		0		0		0		0		0	
Mean	\$844		\$764		\$283		\$386		\$331		\$266	
SD	\$5070		\$4155		\$3486		\$2696		\$1980		\$2059	
Median	\$0		\$0		\$0		\$0		\$0		\$0	
All-cause Ancillary Care Had ≥1 ancillary care visit, n (%)	2112	(82)	1064	(75)	908	(64)	834	(59)	588	(50)	766	(66)
Number of ancillary care visits												
Mean	8		6		3		3		3		3	
SD	12		10		5		6		8		6	
Median	4		3		1		1		1		1	
Total ancillary care costs (2012												

• •	Overa Coho			Ac	ditionall	v Trea	ted[a]		Suppo	ortive	Care Onl	víal		
		Periods Of All-Cause Utilization and Costs Asse									Supportive Care Only[a] sessment [b]			
	Follow	Overall Follow-up		Follow-up py		First-line Chemothera py		Second-line Chemotherapy		All Post- first-line Chemothera py		First- Chemo py	thera	
	(N=25	•	(N = 1	•	(N = 1	•	(N = 14	•	(N = 11	•	(N = 1	168)		
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)		
US \$)														
Mean	\$5620		\$4075		\$2277		\$2326		\$1874		\$2858			
SD	\$9634		\$8221		\$4351		\$5604		\$6714		\$4947			
Median	\$2824		\$1160		\$476		\$197		\$0		\$713			
All-cause Total Health Care Utilization														
Had ≥1 medical encounter, n		(10		(10		(10				(98		(10		
(%)	2583	0)	1415	0)	1415	0)	1415	(100)	1149)	1168	0)		
Number of encounters														
Mean	111		86		48		49		36		49			
SD	99		85		39		64		72		48			
Median	81		59		37		30		13		36			
Total costs (2012 US \$)														
	\$104,7		\$70,59		\$48,88				\$33,63		\$53,35			
Mean	86		4		4		\$37,068		3		5			
	\$76,67		\$61,76		\$41,48				\$46,86		\$49,66			
SD	1		2		9		\$41,681		9		5			
NA salina	\$86,28		\$53,68		\$38,30		#00.000		\$18,91		\$41,72			
Median	8		0		0		\$23,890		4		9			

ED = emergency department; SD = standard deviation; SNF = skilled nursing facility; US = United States

[[]a] Patients receiving cancer-related treatments after the first-line chemotherapy completion date were categorized as "additionally treated," and the remaining patients were classified as "supportive care only."

Appendix 4: All-cause Health Care Utilization and Costs during the Entire Follow-up Period - Overall by Treatment

Cohort and Line of Therapy

Overall
Cohort Additionally Treated[a] Supportive Care Only[a]

Periods Of All-Cause Utilization and Costs Assessment [b]

Conort	Au	iditionally freat	Supportive Care Uniy[a]									
Periods Of All-Cause Utilization and Costs Assessment [b]												
Overall Follow-up (N = 2583)	All Post- first-line Chemothera py (N = 1415)	First-line Chemothera py (N = 1415)	Second-line Chemotherapy (N = 1415)	All Post- first-line Chemothera py (N = 1168)	First-line Chemothera py (N = 1168)							
n (%)	n (%)	n (%)	n (%)	n (%)	n (%)							

[[]b] Gastric cancer-related health care utilization and costs were assessed during the following pre-defined periods of assessment: (1) Overall follow-up period: the period between the index gastric cancer diagnosis date and death or the end of the database (December 31, 2009), whichever occurred first; (2) Post–first-line chemotherapy period: the period between the day immediately following the first-line chemotherapy administration end date and death or the end of the database, whichever occurred first; (3) First-line chemotherapy period: the period between the gastric cancer index date and the first-line chemotherapy regimen end date; and (4) Second-line chemotherapy period: the period between the day immediately following the first-line chemotherapy regimen end date and the last date of the second-line chemotherapy regimen among patients who initiated second-line chemotherapy.